



**BioAlliance Pharma**  
The Drug Resistance Company

## **BioAlliance Pharma announces third quarter 2006 consolidated revenues**

Main events include launch preparations for its first product, Loramyc®

Paris, November 15, 2006 -- BioAlliance Pharma SA (Euronext Paris – Code Isin : FR0010095596 - BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today its revenues for Q3 2006.

EUR k IFRS-compliant (excluding taxes)	Q3 – 2006	Q3 – 2005
Revenues	102	30 <sup>(1)</sup>

*(1) Until the end of 2005, BioAlliance Pharma's financial statements were presented according to French accounting rules.*

The EUR 102,000 revenues for Q3 derive from services supplied to Eurofins-VIRalliance (EVI, Inc.) as in Q1 and Q2 2006.

Main events:

1. Loramyc
  - On October 13, the Company announced it had received its first Marketing Authorization. This was granted in France for Loramyc®, the first bioadhesive antifungal treatment for oropharyngeal candidiasis for immuno-depressed patients. The Company has set up a team of scientific staff under Florence Dupre, VP Sales and Marketing, to ensure effective launch preparations for the product. Team members have strong experience in the hospital environment, which they acquired while working for international pharmaceutical groups. Their current priority is to meet hospital clinicians specializing in oncology and infectious diseases. The team has already met with very positive reactions from these specialists, thus confirming that there is a real need among patients.



# BioAlliance Pharma

The Drug Resistance Company

- On October 26, against the backdrop of these preparations, BioAlliance organized a meeting of clinicians who had taken part in the clinical development of Loramyc®. This symposium took place during ECC8, the 8th European Congress of Chemotherapy and Infectiology held in Budapest.

Bertrand Dupont (Hôpital Necker, Paris, France) gave a presentation on the clinical results of Loramyc® for candidiasis in patients infected with HIV, and René Jean Bensadoun (Centre hospitalier Antoine Lacassagne, Nice, France), presented the results of trials on cancer patients who had received radiotherapy with associated mucositis.

The antifungal profile of Loramyc® (miconazole Lauriad®) was the subject of a recent comparative analysis completed according to FDA standards by Professor Mahmoud Ghannoum (Center for Medical Mycology, University Hospital of Cleveland, USA). Prof. Ghannoum presented the results at ECC8. These confirmed that miconazole, the main active ingredient of Loramyc®, remains a reference antifungal for the treatment of oropharyngeal candidiasis, compared to more recent treatments.

## 2. Appointment to the Supervisory Board

- The Supervisory Board meeting of October 25 co-opted Georges Hibon as an independent member of the board, replacing Claude Stoufs (representative of venture capital firm, Capricorn).

Hibon's pharmaceutical experience covers 18 years of European and international activity at Merck, followed by eight years with Pasteur Mérieux Connaught, where his last position on leaving in 1998 was chairman for North America. He is currently an adviser to several companies and organizations in Europe and North America. He has accumulated more than 35 years experience in the pharmaceutical and biotechnology industry. He has a degree from HEC. His other responsibilities include: board member of Cerep (France), Aphton, Inc. (US), and Biomérieux SA (France).

"The arrival of Georges Hibon adds additional strengths to BioAlliance's board," said Dominique Costantini, MD, President and CEO of BioAlliance Pharma. "He brings his remarkable breadth of industry vision and his sound experience of worldwide pharmaceutical markets, especially in the US where the company wishes to develop significantly in the next few years,"



# BioAlliance Pharma

The Drug Resistance Company

## **About BioAlliance Pharma**

BioAlliance Pharma SA (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections.

Specialty pharma targets the development and marketing of drugs for specialist markets and selected populations. This business model, unlike that of "big pharma" which targets general medicine, offers faster product development, lower R&D costs, smaller sales teams, and hence higher margins and fast growth.

The Company is developing three broad product ranges based on the Lauriad(R) adhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities program focused on development of new drugs in oncology and HIV.

The Loramyc(R) (miconazole Lauriad(R)) 50 mg Bioadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. A pivotal Phase III trial of Loramyc(R) is ongoing in the US in 2006 for the same indication. A second product, acyclovir Lauriad(R), for the treatment of oral herpes, has completed a Phase I clinical trial in Europe. A Phase I/II trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug® nanoparticle delivery technology has been completed in Europe, and has been granted orphan drug status by the EMEA and the FDA.

## **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 28 April 2006 under the number R. 06-042, which is available on the AMF website <http://www.amf-france.org> or BioAlliance Pharma S.A.'s website <http://www.bioalliancepharma.com>.*



# BioAlliance Pharma

The Drug Resistance Company

Media and analyst contacts:

***BioAlliance Pharma SA***

**Dominique COSTANTINI**

President and CEO

Tel : +33 1 45 58 76 01

[dominique.costantini@bioalliancepharma.com](mailto:dominique.costantini@bioalliancepharma.com)

**Gilles AVENARD**

Chief Operating Officer

Tel : +33 1 45 58 76 02

[gilles.avenard@bioalliancepharma.com](mailto:gilles.avenard@bioalliancepharma.com)

***ACTUS***

Agnès GILBERT

Tel : +33 1 53 67 36 33

[agilbert@actus.fr](mailto:agilbert@actus.fr)

Nicole ROFFÉ

Tel : +33 1 53 67 35 74

[nroffe@actus.fr](mailto:nroffe@actus.fr)

***Andrew Lloyd & Associates***

Gilles PETITOT

Tel : +33 1 56 54 07 07

[gilles@ala.com](mailto:gilles@ala.com)

Juliette DOS SANTOS

Tel : +33 1 56 54 07 04

[juliette@ala.com](mailto:juliette@ala.com)